Apeiron and other key shareholders enter into voluntary lock-up agreements • This voluntary lock-up extends trading restrictions by 24 months for Apeiron and 12 months for other investors • Demonstrates strong ongoing confidence in atai’s diversified platform and multiple innovative programs designed to address unmet patient need in mental health NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) — atai…


Previous articleEditor’s Choice Award 2021-Best Study on Psychedelics and Neuroplasticity
Next articleAwakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and Business Highlights